Skip to content

Retrospective Study on Anosmias and Ageusias Linked to Infection by Covid-19

Retrospective Study on Anosmias and Ageusias Linked to Infection by SARS-Cov 2

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04681157
Acronym
STras-Cov-2
Enrollment
300
Registered
2020-12-23
Start date
2020-04-03
Completion date
2021-04-03
Last updated
2020-12-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid-19

Keywords

Covid-19, Odor disturbance, Taste disturbances, SARS-Cov2, Anosmia, Ageusia

Brief summary

Odor and taste disturbances have increased dramatically during this time of the COVID-19 pandemic. Currently, we have very little information on the demographic and clinical characteristics of the affected population, on the severity and course of the olfactory / taste loss. The main objective of this research is to analyze the epidemiological, demographic and clinical characteristics of patients suspected or already confirmed of infection with SARS-Cov2 presenting with anosmia and / or ageusia.

Interventions

None listed

Sponsors

University Hospital, Strasbourg, France
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Major subject (≥18 years old) * Subject having had a loss of smell and / or taste that occurred during the period of the Covid-19 epidemic with or without other symptom (s) suggestive of a Covid infection -19 * Subject with suspected or confirmed Covid-19 infection * Subject taken care of by the ENT service * Subject not having expressed his opposition, after information, to the reuse of his data for the purposes of this research.

Exclusion criteria

* Subject having expressed opposition to participating in the study * Subject under guardianship or guardianship * Subject under safeguard of justice

Design outcomes

Primary

MeasureTime frame
Retrospective analysis of demographic and clinical characteristics of patients with suspected or already confirmed SARS-Cov2 infection with anosmia and / or ageusiaThe files analysed retrospectily from February 01, 2020 to June 03, 2020 will be examined]

Countries

France

Contacts

Primary ContactMarion RENAUD, MD
marion.renaud@chru-strasbourg.fr33 3 88 12 61 89
Backup ContactSaïd CHAYER, PhD, HDR
said.chayer@chru-strasbourg.fr33 3 88 11 66 90

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026